Table 1 Patient profile of 1037 COVID-19 confirmed cases as of 30 April 2020 (with data during hospitalisation updated till 10 May 2020)

Demographics

 Age (years)

  Mean ± SD

37.8 ± 17.8

60.6 ± 14.0

37.6 ± 17.5

35.6 ± 16.8

 < 0.0001

  Median

35

62

34

32

  Range

0–96

25–96

0–93

0–89

 Gender

  Male

558 (53.8%)

32 (64.0%)

232 (47.8%)

294 (58.6%)

0.0011

  Female

479 (46.2%)

18 (36.0%)

253 (52.2%)

208 (41.4%)

Chronic diseases^†

 Nil (Without any of 25 selected diseases)

915 (88.2%)

29 (58.0%)

425 (87.6%)

461 (91.8%)

 < 0.0001

 With any of 25 selected diseases

122 (11.8%)

21 (42.0%)

60 (12.4%)

41 (8.2%)

 Hypertension

87 (8.4%)

16 (32.0%)

46 (9.5%)

25 (5.0%)

 < 0.0001

 Hyperlipidemia

62 (6.0%)

12 (24.0%)

30 (6.2%)

20 (4.0%)

 < 0.0001

 Diabetes

33 (3.2%)

6 (12.0%)

15 (3.1%)

12 (2.4%)

0.0011

Source of infection

 Local cases

422 (40.7%)

30 (60.0%)

219 (45.2%)

173 (34.5%)

 < 0.0001

 Imported cases

615 (59.3%)

20 (40.0%)

266 (54.8%)

329 (65.5%)

Symptoms

 With presenting symptoms upon COVID-19 confirmation

844 (81.4%)

48 (96.0%)

406 (83.7%)

390 (77.7%)

0.0013

Duration between symptom onset and admission

 Mean ± SD (Days)

5.8 ± 5.4

5.5 ± 3.7

5.2 ± 4.7

6.4 ± 6.2

0.1650

 Less than 5 days

447 (53.0%)

22 (45.8%)

225 (55.4%)

200 (51.3%)

0.0514

 5–9 days

246 (29.1%)

17 (35.4%)

124 (30.5%)

105 (26.9%)

 10 days or above

151 (17.9%)

9 (18.8%)

57 (14.0%)

85 (21.8%)

Symptoms (incl. data captured during hospitalisation)

 Cough

514 (49.5%)

41 (82.0%)

246 (50.7%)

227 (45.2%)

 < 0.0001

 Fever

495 (47.7%)

40 (80.0%)

242 (49.9%)

213 (42.4%)

 < 0.0001

 Sore Throat

272 (26.2%)

9 (18.0%)

142 (29.3%)

121 (24.1%)

0.0724

 Headache

159 (15.3%)

7 (14.0%)

74 (15.3%)

78 (15.5%)

0.9575

 Diarrhea

117 (11.3%)

9 (18.0%)

61 (12.6%)

47 (9.4%)

0.0856

 Fatigue

110 (10.6%)

9 (18.0%)

53 (10.9%)

48 (9.6%)

0.1726

 Myalgia

109 (10.5%)

9 (18.0%)

51 (10.5%)

49 (9.8%)

0.1938

 Dyspnoea

88 (8.5%)

23 (46.0%)

37 (7.6%)

28 (5.6%)

 < 0.0001

 Chills

77 (7.4%)

9 (18.0%)

42 (8.7%)

26 (5.2%)

0.0016

 Pneumonia

36 (3.5%)

13 (26.0%)

14 (2.9%)

9 (1.8%)

 < 0.0001

 Vomiting

13 (1.3%)

2 (4.0%)

5 (1.0%)

6 (1.2%)

0.1965

 Others not listed above

268 (25.8%)

9 (18.0%)

124 (25.6%)

135 (26.9%)

0.3843

Critical

4

19

4

19

0

0

0

0

Serious

14

21

14

21

0

0

0

0

Stable

461

481

15

5

446

476

0

0

Satisfactory

550

515

16

5

34

8

500

502

Missing

8

1

1

0

5

1

2

0

Treatments

 Anti-viral drugs (Kaletra/ribavirin/interferon)

637 (61.4%)

49 (98.0%)

317 (65.4%)

271 (53.9%)

 < 0.0001

 Corticosteriod drugs

72 (6.9%)

30 (60.0%)

26 (5.4%)

16 (3.2%)

 < 0.0001

 ICU care

53 (5.1%)

39 (78.0%)

10 (2.1%)

4 (0.8%)

 < 0.0001

 Intubation

23 (2.2%)

23 (46.0%)

0 (0.0%)

0 (0.0%)

-

Discharge status (as of 10 May 2020)

 Still hospitalized

50 (4.8%)

10 (20.0%)

25 (5.2%)

15 (3.0%)

 < 0.0001

 Discharged alive

983 (94.8%)

37 (74.0%)

460 (94.8%)

486 (96.8%)

 Deceased

4 (0.4%)

3 (6.0%)

0 (0.0%)

1 (0.2%)

Length of stay (days) (incl. not yet discharged cases)

 Mean ± SD

21.7 ± 11.7

32.7 ± 14.4

22.1 ± 11.5

20.1 ± 11.0

 < 0.0001

 0–7 days

80 (7.7%)

1 (2.0%)

26 (5.4%)

53 (10.6%)

 < 0.0001

 8–14 days

240 (23.1%)

3 (6.0%)

110 (22.7%)

127 (25.3%)

 15–21 days

244 (23.5%)

4 (8.0%)

122 (25.2%)

118 (23.5%)

 22 days or above

473 (45.6%)

42 (84.0%)

227 (46.8%)

204 (40.6%)